S&P 500
5,975.13
+0.7%
+$39.19
DJI
42,512.17
+0.5%
+$206.69
NASDAQ
19,441.51
+1.0%
+$198.90
Bitcoin
106,216.00
+1.9%
+1,999.29
AAPL
$203.06
+0.7%
+$1.36
AMZN
$207.54
+0.4%
+$0.89
GOOG
$169.14
-0.7%
-$1.23
META
$670.29
-0.1%
-$0.61
MSFT
$462.85
+0.2%
+$0.88
NVDA
$141.72
+3.2%
+$4.34
TSLA
$354.18
+3.4%
+$11.49
Enlivex Therapeutics (NASDAQ: ENLV)
$0.95
(-4.5%)
-$0.04
Price as of May 28, 2025, 11:29 a.m. ET
Enlivex Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Enlivex Therapeutics Company Info
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.